Understanding the rise in overdose deaths involving opioids and non-opioid prescription drugs in the United States
Previous studies demonstrate that the reformulation of OxyContin in the U.S. in 2010 induced substitution to illicit opioids, causing illicit opioid markets to grow disproportionately fast in states more exposed to the reformulation. In this paper, we examine if this shift to the illicit market also...
Saved in:
| Published in | The International journal of drug policy p. 104104 |
|---|---|
| Main Authors | , , |
| Format | Journal Article |
| Language | English |
| Published |
Netherlands
Elsevier B.V
06.07.2023
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Previous studies demonstrate that the reformulation of OxyContin in the U.S. in 2010 induced substitution to illicit opioids, causing illicit opioid markets to grow disproportionately fast in states more exposed to the reformulation. In this paper, we examine if this shift to the illicit market also led to a rise in polysubstance overdose deaths involving non-opioid prescription drugs, including gabapentinoids and “Z-drugs” and, separately, benzodiazepines.
Using a difference-in-differences framework, the relationship between exposure to reformulation and overdose death rates including specific substances was studied in each year from 1999 to 2020 while accounting for fixed differences across states, common nationwide shocks, and state-level differences in pain reliever misuse prior to reformulation. Exposure to reformulation was measured as the pre-reformulation rate of OxyContin misuse.
Exposure to reformulation predicted growth in overdose deaths involving gabapentinoids and Z-drugs. There is less evidence that it predicted growth in overdose deaths involving benzodiazepines. However, for all substances, there is strong evidence that pre-reformulation OxyContin misuse rates predicted post-reformulation growth in overdose deaths concurrently involving synthetic opioids.
The opioid crisis has changed in radical ways. This study links a major supply-side intervention to the increase in polysubstance overdose deaths involving non-opioid prescription drugs, specifically gabapentinoids and Z-drugs. |
|---|---|
| AbstractList | Previous studies demonstrate that the reformulation of OxyContin in the U.S. in 2010 induced substitution to illicit opioids, causing illicit opioid markets to grow disproportionately fast in states more exposed to the reformulation. In this paper, we examine if this shift to the illicit market also led to a rise in polysubstance overdose deaths involving non-opioid prescription drugs, including gabapentinoids and “Z-drugs” and, separately, benzodiazepines.
Using a difference-in-differences framework, the relationship between exposure to reformulation and overdose death rates including specific substances was studied in each year from 1999 to 2020 while accounting for fixed differences across states, common nationwide shocks, and state-level differences in pain reliever misuse prior to reformulation. Exposure to reformulation was measured as the pre-reformulation rate of OxyContin misuse.
Exposure to reformulation predicted growth in overdose deaths involving gabapentinoids and Z-drugs. There is less evidence that it predicted growth in overdose deaths involving benzodiazepines. However, for all substances, there is strong evidence that pre-reformulation OxyContin misuse rates predicted post-reformulation growth in overdose deaths concurrently involving synthetic opioids.
The opioid crisis has changed in radical ways. This study links a major supply-side intervention to the increase in polysubstance overdose deaths involving non-opioid prescription drugs, specifically gabapentinoids and Z-drugs. BACKGROUNDPrevious studies demonstrate that the reformulation of OxyContin in the U.S. in 2010 induced substitution to illicit opioids, causing illicit opioid markets to grow disproportionately fast in states more exposed to the reformulation. In this paper, we examine if this shift to the illicit market also led to a rise in polysubstance overdose deaths involving non-opioid prescription drugs, including gabapentinoids and "Z-drugs" and, separately, benzodiazepines.METHODSUsing a difference-in-differences framework, the relationship between exposure to reformulation and overdose death rates including specific substances was studied in each year from 1999 to 2020 while accounting for fixed differences across states, common nationwide shocks, and state-level differences in pain reliever misuse prior to reformulation. Exposure to reformulation was measured as the pre-reformulation rate of OxyContin misuse.RESULTSExposure to reformulation predicted growth in overdose deaths involving gabapentinoids and Z-drugs. There is less evidence that it predicted growth in overdose deaths involving benzodiazepines. However, for all substances, there is strong evidence that pre-reformulation OxyContin misuse rates predicted post-reformulation growth in overdose deaths concurrently involving synthetic opioids.DISCUSSIONThe opioid crisis has changed in radical ways. This study links a major supply-side intervention to the increase in polysubstance overdose deaths involving non-opioid prescription drugs, specifically gabapentinoids and Z-drugs. |
| ArticleNumber | 104104 |
| Author | Peet, Evan D. Pacula, Rosalie Liccardo Powell, David |
| Author_xml | – sequence: 1 givenname: David surname: Powell fullname: Powell, David email: dpowell@rand.org organization: RAND Corporation, 1200 South Hayes Street, Arlington, VA 22202 USA – sequence: 2 givenname: Evan D. surname: Peet fullname: Peet, Evan D. organization: RAND Corporation, 4570 Fifth Ave, Pittsburgh, PA 15213 USA – sequence: 3 givenname: Rosalie Liccardo surname: Pacula fullname: Pacula, Rosalie Liccardo organization: University of Southern California, 635 Downey Way VPD 514J, Los Angeles, CA 90089 USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37422359$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kE1rGzEQhkVJaJyk_6AUHXNZR5-72kshhDYtBHpIfBZraWTL2NJWkg3599V2kxwDA5oZnndm9F6isxADIPSVkiUltL3dLW06bsa4ZITx2hI1PqEFVR1vRCfVGVqQXsqG97K_QJc57wipkKCf0QXvBGNc9guUVsFCymUI1ocNLlvAyWfAPuB4gmRjzS0MZZtr6xT3p4mKo4_eZlxFuF7VzDUeE2ST_Fh8DHg6btL8H7kKvoDFT2UokK_RuRv2Gb68vldo9fPH8_2v5vHPw-_7u8fGsK4rjZXOGeao49K21AlilDBro3rjnGVcUdm3bdspSZWQyim65t0gLWVSdkIKw6_QzTx3TPHvEXLRB58N7PdDgHjMmikumSJcsIqKGTUp5pzA6TH5w5BeNCV6clvv9Oy2ntzWs9tV9u11w3F9APsuerO3At9nAOo_Tx6SzsZDMGB9AlO0jf7jDf8APByVqg |
| CitedBy_id | crossref_primary_10_1016_j_drugpo_2024_104416 |
| Cites_doi | 10.2147/JPR.S345521 10.1097/ADT.0000000000000127 10.1371/journal.pmed.1003709 10.1016/j.lana.2022.100190 10.1007/s40265-017-0700-x 10.1192/j.eurpsy.2021.2219 10.1136/bmjopen-2021-053487 10.15585/mmwr.mm7119a3 10.1016/j.drugalcdep.2021.109001 10.21037/apm.2019.12.09 10.1002/pds.3658 10.1016/j.amepre.2016.02.014 10.1377/hlthaff.2018.05232 10.1257/pol.20170082 10.1177/0897190013515001 10.1097/JCP.0b013e31822bb378 10.1016/j.drugalcdep.2016.07.024 10.1016/j.japh.2021.10.020 10.1016/j.addbeh.2020.106680 10.1001/jamainternmed.2019.0086 10.15585/mmwr.mm7129e2 10.1162/ajhe_a_00101 10.1016/j.amepre.2019.06.007 10.1111/add.14144 10.1001/jamapsychiatry.2014.3043 10.2105/AJPH.2019.305412 10.1371/journal.pmed.1002965 10.1093/epirev/mxaa011 10.1111/add.13324 10.1093/eurpub/ckac161 10.1016/S0140-6736(21)02252-2 10.1136/bmjopen-2020-038692 10.1016/j.amepre.2015.03.040 10.1016/S2468-2667(19)30128-8 10.24095/hpcdp.38.6.02 10.1093/sleep/zsy264 10.1002/hec.3944 10.1111/bcp.14397 10.1111/ajt.16053 10.15585/mmwr.mm6712a1 10.1162/rest_a_00755 10.1097/YCO.0000000000000717 10.1001/jamainternmed.2022.5268 10.1016/j.jpain.2005.05.004 10.1001/jamapsychiatry.2019.2563 10.1111/j.1360-0443.2008.02248.x 10.1016/j.euroneuro.2017.08.430 10.2105/AJPH.2016.303627 10.1001/jamanetworkopen.2020.31647 10.1176/appi.ajp.2020.20071038 10.1016/j.ssmph.2017.01.009 10.1093/aje/kwab290 10.1086/716462 10.1159/000521996 10.7326/M21-4656 10.1016/j.jhealeco.2020.102408 10.1001/jama.2022.10100 10.1146/annurev-publhealth-031914-122957 10.1002/adaw.33367 10.1111/bcp.14537 10.15585/mmwr.mm7034a4 10.1086/713378 10.1080/14737175.2016.1202764 10.1038/s41380-020-00949-3 10.1086/711723 10.1093/qje/qjab043 |
| ContentType | Journal Article |
| Copyright | 2023 Elsevier B.V. Copyright © 2023 Elsevier B.V. All rights reserved. |
| Copyright_xml | – notice: 2023 Elsevier B.V. – notice: Copyright © 2023 Elsevier B.V. All rights reserved. |
| DBID | NPM AAYXX CITATION 7X8 |
| DOI | 10.1016/j.drugpo.2023.104104 |
| DatabaseName | PubMed CrossRef MEDLINE - Academic |
| DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Social Welfare & Social Work Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1873-4758 |
| EndPage | 104104 |
| ExternalDocumentID | 10_1016_j_drugpo_2023_104104 37422359 S0955395923001512 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: NCIPC CDC HHS grantid: R01 CE002999 – fundername: NIDA NIH HHS grantid: R21 DA052655 – fundername: NIDA NIH HHS grantid: P50 DA046351 |
| GroupedDBID | --- --K --M ..I .1- .FO .~1 0R~ 0SF 1B1 1P~ 1~. 1~5 29J 4.4 457 4G. 53G 5GY 5VS 7-5 71M 8P~ AACTN AAEDT AAEDW AAFJI AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATCM AAWTL AAXUO ABBQC ABFNM ABIVO ABJNI ABLVK ABMAC ABMMH ABMZM ABXDB ABYKQ ABZDS ACDAQ ACGFS ACHQT ACIUM ACRLP ADBBV ADEZE ADMUD AEBSH AEKER AEVXI AFCTW AFKWA AFRHN AFTJW AFXIZ AGHFR AGUBO AGYEJ AIEXJ AIKHN AITUG AJBFU AJOXV AJRQY AJUYK AKYCK ALCLG ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX AOMHK ASPBG AVARZ AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 DU5 EBS EFJIC EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-Q GBLVA HVGLF HZ~ IHE J1W KOM LCYCR M41 MO0 N9A NCXOZ O-L O9- OAUVE OGGZJ OZT P-8 P-9 P2P PC. PQQKQ PRBVW Q38 R2- RIG ROL RPZ SCC SDF SDG SDP SEL SES SEW SPCBC SSB SSH SSO SSP SSZ T5K UHS Z5R ~G- AAXKI ADVLN AFJKZ AKRWK NPM AAYXX CITATION 7X8 |
| ID | FETCH-LOGICAL-c277t-d5ffc2f1f35d61f40c84cbc89cffd23815966678518458f81b37a5d12557454c3 |
| IEDL.DBID | AIKHN |
| ISSN | 0955-3959 |
| IngestDate | Fri Oct 25 08:11:58 EDT 2024 Thu Sep 26 15:50:14 EDT 2024 Sat Nov 02 12:29:19 EDT 2024 Fri Feb 23 02:37:14 EST 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | Z-drugs Opioid crisis OxyContin reformulation Benzodiazepines Illicit drug markets Gabapentinoids |
| Language | English |
| License | Copyright © 2023 Elsevier B.V. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c277t-d5ffc2f1f35d61f40c84cbc89cffd23815966678518458f81b37a5d12557454c3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 37422359 |
| PQID | 2835280342 |
| PQPubID | 23479 |
| PageCount | 1 |
| ParticipantIDs | proquest_miscellaneous_2835280342 crossref_primary_10_1016_j_drugpo_2023_104104 pubmed_primary_37422359 elsevier_sciencedirect_doi_10_1016_j_drugpo_2023_104104 |
| PublicationCentury | 2000 |
| PublicationDate | 2023-Jul-06 |
| PublicationDateYYYYMMDD | 2023-07-06 |
| PublicationDate_xml | – month: 07 year: 2023 text: 2023-Jul-06 day: 06 |
| PublicationDecade | 2020 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | The International journal of drug policy |
| PublicationTitleAlternate | Int J Drug Policy |
| PublicationYear | 2023 |
| Publisher | Elsevier B.V |
| Publisher_xml | – name: Elsevier B.V |
| References | Kheirabadi, Salehi, Bahrami, Maracy (bib0036) 2018; 17 Zhao, Baek, Hume, McPhillips, Lapane (bib0077) 2022 Bykov, Bateman, Franklin, Vine, Patorno (bib0007) 2020; 3 Enos (bib0014) 2022; 34 IQVIA. 2020. “Medicine Spending and Affordability in the United States.” Sharma, Simpson, Samanani, Jess, Eurich (bib0064) 2020; 10 Aldy, Mustaquim, Campleman, Meyn, Abston, Krotulski, Logan, Gladden, Hughes, Amaducci (bib0001) 2021; 70 Park, Powell (bib0050) 2021 Sun, Dixit, Humphreys, Darnall, Baker, Mackey (bib0066) 2017 Kariisa, Seth, Scholl, Wilson, Davis (bib0034) 2021; 227 Vozoris (bib0073) 2019; 42 Pardo, Caulkins, Kilmer, Pacula, Reuter, Stein (bib0049) 2019 (bib0070) 2017 Esechie, Kuo, Goodwin, Westra, Raji (bib0015) 2021; 11 Macleod, Steer, Tilling, Cornish, Marsden, Millar, Strang, Hickman (bib0043) 2019; 16 Pierce, van Amsterdam, Kalkman, Schellekens, den Brink (bib0053) 2021; 64 Kalkman, Kramers, van Dongen, den Brink, Schellekens (bib0032) 2019; 4 Sessler, Downing, Kale, Chilcoat, Baumgartner, Coplan (bib0062) 2014; 23 Evoy, Morrison, Saklad (bib0018) 2017; 77 Zhang, Strahan, Guy, Larochelle (bib0075) 2022 Alpert, Powell, Pacula (bib0002) 2018; 10 Oueini, Goodin, Hincapie-Castillo, Vouri (bib0048) 2022; 62 Goodwin, Moeller, Zhu, Yarden, Ganzhorn, Williams (bib0020) 2021; 113 Seth, Scholl, Rudd, Bacon (bib0063) 2018; 67 Evans, Lieber, Power (bib0017) 2019; 101 Hockenhull, Amioka, Black, Forber, Haynes, Wood, Dart, Dargan (bib0022) 2021; 87 Jones, Bekheet, Park, Alexander (bib0029) 2020; 42 Ray, Chung, Murray, Malow, Daugherty, Michael Stein (bib0056) 2021; 18 Ruhm (bib0057) 2017 Compton, Valentino, DuPont (bib0013) 2021; 26 Mattson, Chowdhury, Gilson (bib0045) 2022; 71 Zhang, Olfson, King (bib0076) 2019; 76 McCall Jones, Baldwin, Compton (bib0046) 2017; 107 Powell, Alpert, Pacula (bib0054) 2019; 38 Townsend, Kline, Rivera-Aguirre, Bunting, Mauro, Marshall, Martins, Cerdá (bib0069) 2022; 191 Bonnet, Scherbaum (bib0005) 2017; 27 Mackenzie-Liu (bib0042) 2021; 95 Cicero, Ellis (bib0010) 2015; 72 Kolodny, Courtwright, Hwang, Kreiner, Eadie, Clark, Alexander (bib0038) 2015 Calandre, Rico-Villademoros, Slim (bib0008) 2016; 16 Salehi, Kheirabadi, Maracy, Ranjkesh (bib0060) 2011; 31 Lisa, Jessica (bib0040) 2018; 38 Peckham, Evoy, Ochs, Covvey (bib0051) 2018; 12 Cicero, Ellis, Kasper (bib0012) 2020; 110 (bib0026) 2022 Meinhofer (bib0047) 2018; 4 Kalkman, Brink, Pierce, Atsma, Vissers, Schers, Dongen, Kramers, Schellekens (bib0031) 2022; 28 Peet, Dana, Sheng, Powell, Shetty, Stein (bib0052) 2023; 183 Tardelli, Bianco, Prakash, Segura, Castaldelli-Maia, Fidalgo, Martins (bib0068) 2022 Beheshti (bib0004) 2019; 28 Boon, van Dorp, Broens, Overdyk (bib0006) 2020; 9 Kuehn (bib0039) 2022; 327 (bib0072) 2019 Jann, Kennedy, Lopez (bib0028) 2014; 27 Ruhm (bib0058) 2018; 113 Kheirabadi, Ranjkesh, Maracy, Salehi (bib0035) 2008 Alpert, Evans, Lieber, Powell (bib0003) 2022; 137 Russell, Law, Bonn, Rehm, Ali (bib0059) 2023 Yarborough, Stumbo, Janoff, Yarborough, McCarty, Chilcoat, Coplan, Green (bib0074) 2016 Sarker, Al-Garadi, Ge, Nataraj, McGlone, Jones, Sumner (bib0061) 2022; 32 Szmulewicz, Bateman, Levin, Huybrechts (bib0067) 2021; 178 Evans, Harris, Kessler (bib0016) 2022 Smith, Havens, Walsh (bib0065) 2016; 111 Hockenhull, Black, Haynes, Rockhill, Dargan, Dart, Wood (bib0023) 2021; 87 Hwang, Kang, Kornegay, Staffa, Jones, McAninch (bib0025) 2016; 51 Ciccarone (bib0009) 2021; 34 Guy Jr, Gery, Zhang, Halpin, Sargent (bib0021) 2019; 57 Kariisa, Davis, Kumar, Seth, Mattson, Chowdhury, Jones (bib0033) 2022; 71 Kim (bib0037) 2021; 75 Powell, Pacula (bib0055) 2021; 7 Goodman, Brett (bib0019) 2019; 179 Humphreys, Shover, Andrews, Bohnert, Brandeau, Caulkins, Chen, Cuéllar, Hurd, Juurlink (bib0024) 2022; 399 Jones, McAninch (bib0030) 2015; 49 Liu, O'Donnell, Gladden, McGlone, Chowdhury (bib0041) 2021; 21 Cicero, Inciardi, Munoz (bib0011) 2005; 6 Mallatt (bib0044) 2022 (bib0071) 2018 Zhang (10.1016/j.drugpo.2023.104104_bib0075) 2022 Goodman (10.1016/j.drugpo.2023.104104_bib0019) 2019; 179 Powell (10.1016/j.drugpo.2023.104104_bib0055) 2021; 7 Pierce (10.1016/j.drugpo.2023.104104_bib0053) 2021; 64 Zhang (10.1016/j.drugpo.2023.104104_bib0076) 2019; 76 Ruhm (10.1016/j.drugpo.2023.104104_bib0058) 2018; 113 Hwang (10.1016/j.drugpo.2023.104104_bib0025) 2016; 51 Alpert (10.1016/j.drugpo.2023.104104_bib0003) 2022; 137 Meinhofer (10.1016/j.drugpo.2023.104104_bib0047) 2018; 4 Zhao (10.1016/j.drugpo.2023.104104_bib0077) 2022 Boon (10.1016/j.drugpo.2023.104104_bib0006) 2020; 9 (10.1016/j.drugpo.2023.104104_bib0070) 2017 Evoy (10.1016/j.drugpo.2023.104104_bib0018) 2017; 77 Goodwin (10.1016/j.drugpo.2023.104104_bib0020) 2021; 113 Humphreys (10.1016/j.drugpo.2023.104104_bib0024) 2022; 399 Seth (10.1016/j.drugpo.2023.104104_bib0063) 2018; 67 Kim (10.1016/j.drugpo.2023.104104_bib0037) 2021; 75 Esechie (10.1016/j.drugpo.2023.104104_bib0015) 2021; 11 Mallatt (10.1016/j.drugpo.2023.104104_bib0044) 2022 Kariisa (10.1016/j.drugpo.2023.104104_bib0033) 2022; 71 Peet (10.1016/j.drugpo.2023.104104_bib0052) 2023; 183 Macleod (10.1016/j.drugpo.2023.104104_bib0043) 2019; 16 Jones (10.1016/j.drugpo.2023.104104_bib0029) 2020; 42 Liu (10.1016/j.drugpo.2023.104104_bib0041) 2021; 21 Beheshti (10.1016/j.drugpo.2023.104104_bib0004) 2019; 28 Cicero (10.1016/j.drugpo.2023.104104_bib0011) 2005; 6 Ray (10.1016/j.drugpo.2023.104104_bib0056) 2021; 18 Oueini (10.1016/j.drugpo.2023.104104_bib0048) 2022; 62 Salehi (10.1016/j.drugpo.2023.104104_bib0060) 2011; 31 10.1016/j.drugpo.2023.104104_bib0027 Hockenhull (10.1016/j.drugpo.2023.104104_bib0022) 2021; 87 Cicero (10.1016/j.drugpo.2023.104104_bib0012) 2020; 110 Cicero (10.1016/j.drugpo.2023.104104_bib0010) 2015; 72 McCall Jones (10.1016/j.drugpo.2023.104104_bib0046) 2017; 107 Bykov (10.1016/j.drugpo.2023.104104_bib0007) 2020; 3 Evans (10.1016/j.drugpo.2023.104104_bib0016) 2022 Tardelli (10.1016/j.drugpo.2023.104104_bib0068) 2022 Jann (10.1016/j.drugpo.2023.104104_bib0028) 2014; 27 (10.1016/j.drugpo.2023.104104_bib0072) 2019 Calandre (10.1016/j.drugpo.2023.104104_bib0008) 2016; 16 Ruhm (10.1016/j.drugpo.2023.104104_bib0057) 2017 Peckham (10.1016/j.drugpo.2023.104104_bib0051) 2018; 12 Sharma (10.1016/j.drugpo.2023.104104_bib0064) 2020; 10 (10.1016/j.drugpo.2023.104104_bib0026) 2022 Pardo (10.1016/j.drugpo.2023.104104_bib0049) 2019 Kheirabadi (10.1016/j.drugpo.2023.104104_bib0035) 2008 Mattson (10.1016/j.drugpo.2023.104104_bib0045) 2022; 71 Yarborough (10.1016/j.drugpo.2023.104104_bib0074) 2016 Kolodny (10.1016/j.drugpo.2023.104104_bib0038) 2015 Mackenzie-Liu (10.1016/j.drugpo.2023.104104_bib0042) 2021; 95 Hockenhull (10.1016/j.drugpo.2023.104104_bib0023) 2021; 87 Vozoris (10.1016/j.drugpo.2023.104104_bib0073) 2019; 42 Compton (10.1016/j.drugpo.2023.104104_bib0013) 2021; 26 Kalkman (10.1016/j.drugpo.2023.104104_bib0031) 2022; 28 Bonnet (10.1016/j.drugpo.2023.104104_bib0005) 2017; 27 Szmulewicz (10.1016/j.drugpo.2023.104104_bib0067) 2021; 178 Alpert (10.1016/j.drugpo.2023.104104_bib0002) 2018; 10 Lisa (10.1016/j.drugpo.2023.104104_bib0040) 2018; 38 Aldy (10.1016/j.drugpo.2023.104104_bib0001) 2021; 70 Powell (10.1016/j.drugpo.2023.104104_bib0054) 2019; 38 Enos (10.1016/j.drugpo.2023.104104_bib0014) 2022; 34 Townsend (10.1016/j.drugpo.2023.104104_bib0069) 2022; 191 Kuehn (10.1016/j.drugpo.2023.104104_bib0039) 2022; 327 Sarker (10.1016/j.drugpo.2023.104104_bib0061) 2022; 32 (10.1016/j.drugpo.2023.104104_bib0071) 2018 Smith (10.1016/j.drugpo.2023.104104_bib0065) 2016; 111 Evans (10.1016/j.drugpo.2023.104104_bib0017) 2019; 101 Sessler (10.1016/j.drugpo.2023.104104_bib0062) 2014; 23 Russell (10.1016/j.drugpo.2023.104104_bib0059) 2023 Jones (10.1016/j.drugpo.2023.104104_bib0030) 2015; 49 Kariisa (10.1016/j.drugpo.2023.104104_bib0034) 2021; 227 Ciccarone (10.1016/j.drugpo.2023.104104_bib0009) 2021; 34 Sun (10.1016/j.drugpo.2023.104104_bib0066) 2017 Kalkman (10.1016/j.drugpo.2023.104104_bib0032) 2019; 4 Guy Jr, Gery (10.1016/j.drugpo.2023.104104_bib0021) 2019; 57 Park (10.1016/j.drugpo.2023.104104_bib0050) 2021 Kheirabadi (10.1016/j.drugpo.2023.104104_bib0036) 2018; 17 |
| References_xml | – year: 2022 ident: bib0026 publication-title: ICD List – start-page: 443 year: 2022 ident: bib0077 article-title: Geographic variation in the use of gabapentinoids and opioids for pain in a commercially insured adult population in the United States publication-title: Journal of Pain Research contributor: fullname: Lapane – start-page: 219 year: 2017 end-page: 226 ident: bib0057 article-title: Drug involvement in fatal overdoses publication-title: SSM-Population Health contributor: fullname: Ruhm – volume: 75 year: 2021 ident: bib0037 article-title: Must-access prescription drug monitoring programs and the opioid overdose epidemic: The unintended consequences publication-title: Journal of Health Economics contributor: fullname: Kim – volume: 10 year: 2020 ident: bib0064 article-title: Concurrent use of opioids and benzodiazepines/Z-drugs in Alberta, Canada and the risk of hospitalisation and death: A case cross-over study publication-title: BMJ Open contributor: fullname: Eurich – volume: 16 start-page: 1263 year: 2016 end-page: 1277 ident: bib0008 article-title: Alpha2delta ligands, gabapentin, pregabalin and mirogabalin: A review of their clinical pharmacology and therapeutic use publication-title: Expert Review of Neurotherapeutics contributor: fullname: Slim – volume: 87 start-page: 1676 year: 2021 end-page: 1683 ident: bib0023 article-title: Nonmedical use of benzodiazepines and Z-drugs in the UK publication-title: British Journal of Clinical Pharmacology contributor: fullname: Wood – volume: 71 start-page: 940 year: 2022 ident: bib0033 article-title: Vital signs: Drug overdose deaths, by selected sociodemographic and social determinants of health characteristics—25 states and the District of Columbia, 2019–2020 publication-title: Morbidity and Mortality Weekly Report contributor: fullname: Jones – volume: 17 start-page: 55 year: 2018 end-page: 64 ident: bib0036 article-title: Gabapentin, pregabalin, and placebo in reducing opioid withdrawal symptoms in opioid-dependent individuals: A randomized-controlled trial publication-title: Addictive Disorders & Their Treatment contributor: fullname: Maracy – volume: 62 start-page: 468 year: 2022 end-page: 474 ident: bib0048 article-title: Co-utilization of opioids and nonbenzodiazepine hypnotic drugs in US ambulatory care visits, 2006–2016 publication-title: Journal of the American Pharmacists Association contributor: fullname: Vouri – year: 2017 ident: bib0066 article-title: Association between concurrent use of prescription opioids and benzodiazepines and overdose: Retrospective analysis publication-title: BMJ contributor: fullname: Mackey – volume: 67 start-page: 349 year: 2018 ident: bib0063 article-title: Overdose deaths involving opioids, cocaine, and psychostimulants—United States, 2015–2016 publication-title: Morbidity and Mortality Weekly Report contributor: fullname: Bacon – volume: 399 start-page: 555 year: 2022 end-page: 604 ident: bib0024 article-title: Responding to the opioid crisis in North America and beyond: Recommendations of the Stanford–Lancet commission publication-title: The Lancet contributor: fullname: Juurlink – volume: 10 start-page: 1 year: 2018 end-page: 35 ident: bib0002 article-title: Supply-side drug policy in the presence of substitutes: Evidence from the introduction of abuse-deterrent opioids publication-title: American Economic Journal-Economic Policy contributor: fullname: Pacula – volume: 113 start-page: 1339 year: 2018 end-page: 1344 ident: bib0058 article-title: Corrected US opioid-involved drug poisoning deaths and mortality rates, 1999–2015 publication-title: Addiction contributor: fullname: Ruhm – volume: 31 start-page: 593 year: 2011 end-page: 596 ident: bib0060 article-title: Importance of gabapentin dose in treatment of opioid withdrawal publication-title: Journal of clinical psychopharmacology contributor: fullname: Ranjkesh – year: 2022 ident: bib0016 article-title: The hazards of unwinding the prescription opioid epidemic: Implications for child maltreatment publication-title: American Economic Journal: Economic Policy contributor: fullname: Kessler – start-page: 49 year: 2016 end-page: 56 ident: bib0074 article-title: Understanding opioid overdose characteristics involving prescription and illicit opioids: A mixed methods analysis publication-title: Drug and Alcohol Dependence contributor: fullname: Green – volume: 110 start-page: 244 year: 2020 end-page: 250 ident: bib0012 article-title: Polysubstance use: A broader understanding of substance use during the opioid crisis publication-title: American Journal of Public Health contributor: fullname: Kasper – volume: 95 start-page: 36 year: 2021 end-page: 65 ident: bib0042 article-title: From fostering hope to lingering harm: The unintended impact of the OxyContin reformulation on child welfare utilization publication-title: Social Service Review contributor: fullname: Mackenzie-Liu – volume: 4 start-page: e498 year: 2019 end-page: e505 ident: bib0032 article-title: Trends in use and misuse of opioids in the Netherlands: A retrospective, multi-source database study publication-title: The Lancet Public Health contributor: fullname: Schellekens – volume: 137 start-page: 1139 year: 2022 end-page: 1179 ident: bib0003 article-title: Origins of the opioid crisis and its enduring impacts publication-title: The Quarterly Journal of Economics contributor: fullname: Powell – volume: 179 start-page: 695 year: 2019 end-page: 701 ident: bib0019 article-title: A clinical overview of off-label use of gabapentinoid drugs publication-title: JAMA Internal Medicine contributor: fullname: Brett – volume: 28 start-page: 231 year: 2022 end-page: 240 ident: bib0031 article-title: Monitoring opioids in Europe: The need for shared definitions and measuring drivers of opioid use and related harms publication-title: European Addiction Research contributor: fullname: Schellekens – volume: 42 start-page: zsy264 year: 2019 ident: bib0073 article-title: Benzodiazepine and opioid co-usage in the US population, 1999–2014: An exploratory analysis publication-title: Sleep contributor: fullname: Vozoris – volume: 72 start-page: 424 year: 2015 end-page: 430 ident: bib0010 article-title: Abuse-deterrent formulations and the prescription opioid abuse epidemic in the United States: Lessons learned from OxyContin publication-title: JAMA Psychiatry contributor: fullname: Ellis – volume: 70 start-page: 1177 year: 2021 ident: bib0001 article-title: Notes from the field: Illicit benzodiazepines detected in patients evaluated in Emergency Departments for Suspected Opioid Overdose—Four States, October 6, 2020–March 9, 2021 publication-title: Morbidity and Mortality Weekly Report contributor: fullname: Amaducci – volume: 34 start-page: 344 year: 2021 end-page: 350 ident: bib0009 article-title: The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis publication-title: Current Opinion in Psychiatry contributor: fullname: Ciccarone – year: 2017 ident: bib0070 article-title: Global Smart Update: Non-medical use of benzodiazepines: A growing threat to public health? – year: 2019 ident: bib0072 article-title: FDA warns about serious breathing problems with seizure and nerve pain medicines gabapentin (Neurontin, Gralise, Horizant) and pregabalin (Lyrica, Lyrica CR) when used with CNS depressants or in patients with lung problems – volume: 111 start-page: 1160 year: 2016 end-page: 1174 ident: bib0065 article-title: Gabapentin misuse, abuse and diversion: A systematic review publication-title: Addiction contributor: fullname: Walsh – volume: 191 start-page: 599 year: 2022 end-page: 612 ident: bib0069 article-title: Racial/Ethnic and geographic trends in combined stimulant/opioid overdoses, 2007–2019 publication-title: American Journal of Epidemiology contributor: fullname: Cerdá – volume: 9 start-page: 542 year: 2020 end-page: 557 ident: bib0006 article-title: Combining opioids and benzodiazepines: Effects on mortality and severe adverse respiratory events publication-title: Annals of Palliative Medicine contributor: fullname: Overdyk – volume: 42 start-page: 154 year: 2020 end-page: 166 ident: bib0029 article-title: The evolving overdose epidemic: Synthetic opioids and rising stimulant-related harms publication-title: Epidemiologic Reviews contributor: fullname: Alexander – volume: 7 start-page: 41 year: 2021 end-page: 67 ident: bib0055 article-title: The evolving consequences of OxyContin reformulation on drug overdoses publication-title: American Journal of Health Economics contributor: fullname: Pacula – volume: 18 year: 2021 ident: bib0056 article-title: Mortality and concurrent use of opioids and hypnotics in older patients: A retrospective cohort study publication-title: PLoS Medicine contributor: fullname: Michael Stein – start-page: 559 year: 2015 end-page: 574 ident: bib0038 article-title: The prescription opioid and heroin crisis: A public health approach to an epidemic of addiction publication-title: Annual Review of Public Health contributor: fullname: Alexander – volume: 21 start-page: 3794 year: 2021 end-page: 3800 ident: bib0041 article-title: Trends in nonfatal and fatal overdoses involving benzodiazepines—38 states and the District of Columbia, 2019–2020 publication-title: American Journal of Transplantation contributor: fullname: Chowdhury – volume: 64 year: 2021 ident: bib0053 article-title: Is Europe facing an opioid crisis like the United States? An analysis of opioid use and related adverse effects in 19 European countries between 2010 and 2018 publication-title: European Psychiatry contributor: fullname: den Brink – volume: 27 start-page: 1185 year: 2017 end-page: 1215 ident: bib0005 article-title: How addictive are gabapentin and pregabalin? A systematic review publication-title: European Neuropsychopharmacology contributor: fullname: Scherbaum – volume: 11 year: 2021 ident: bib0015 article-title: Trends in prescribing pattern of opioid and benzodiazepine substitutes among Medicare Part D beneficiaries from 2013 to 2018: A retrospective study publication-title: BMJ Open contributor: fullname: Raji – volume: 87 start-page: 1684 year: 2021 end-page: 1694 ident: bib0022 article-title: Non-medical use of benzodiazepines and GABA analogues in Europe publication-title: British Journal of Clinical Pharmacology contributor: fullname: Dargan – volume: 71 start-page: 664 year: 2022 ident: bib0045 article-title: Notes from the field: Trends in gabapentin detection and involvement in drug overdose deaths—23 states and the District of Columbia, 2019–2020 publication-title: Morbidity and Mortality Weekly Report contributor: fullname: Gilson – volume: 76 start-page: 1208 year: 2019 end-page: 1210 ident: bib0076 article-title: Opioid and benzodiazepine coprescribing in the United States before and after US Food and Drug Administration boxed warning publication-title: JAMA Psychiatry contributor: fullname: King – volume: 32 start-page: 939 year: 2022 end-page: 941 ident: bib0061 article-title: Evidence of the emergence of illicit benzodiazepines from online drug forums publication-title: European Journal of Public Health contributor: fullname: Sumner – volume: 3 year: 2020 ident: bib0007 article-title: Association of gabapentinoids with the risk of opioid-related adverse events in surgical patients in the United States publication-title: JAMA Network Open contributor: fullname: Patorno – year: 2023 ident: bib0059 article-title: The increase in benzodiazepine-laced drugs and related risks in Canada: The urgent need for effective and sustainable solutions publication-title: International Journal of Drug Policy contributor: fullname: Ali – volume: 16 year: 2019 ident: bib0043 article-title: Prescription of benzodiazepines, z-drugs, and gabapentinoids and mortality risk in people receiving opioid agonist treatment: Observational study based on the UK Clinical Practice Research Datalink and Office for National Statistics death records publication-title: PLoS Medicine contributor: fullname: Hickman – volume: 107 start-page: 430 year: 2017 end-page: 432 ident: bib0046 article-title: Recent increases in cocaine-related overdose deaths and the role of opioids publication-title: American journal of public health contributor: fullname: Compton – volume: 183 start-page: 162 year: 2023 end-page: 164 ident: bib0052 article-title: Trends in the concurrent prescription of opioids and Gabapentin in the US, 2006 to 2018 publication-title: JAMA Internal Medicine contributor: fullname: Stein – year: 2022 ident: bib0068 article-title: Overdose deaths involving non-BZD hypnotic/sedatives in the USA: Trends analyses publication-title: The Lancet Regional Health-Americas contributor: fullname: Martins – volume: 57 start-page: 629 year: 2019 end-page: 636 ident: bib0021 article-title: An examination of concurrent opioid and benzodiazepine prescribing in 9 states, 2015 publication-title: American Journal of Preventive Medicine contributor: fullname: Sargent – year: 2021 ident: bib0050 article-title: Is the rise in illicit opioids affecting labor supply and disability claiming rates? publication-title: Journal of Health Economics contributor: fullname: Powell – volume: 6 start-page: 662 year: 2005 end-page: 672 ident: bib0011 article-title: Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004 publication-title: The Journal of Pain contributor: fullname: Munoz – volume: 113 year: 2021 ident: bib0020 article-title: The potential role of cocaine and heroin co-use in the opioid epidemic in the United States publication-title: Addictive Behaviors contributor: fullname: Williams – volume: 12 year: 2018 ident: bib0051 article-title: Gabapentin for off-label use: Evidence-based or cause for concern? publication-title: Substance Abuse: Research and Treatment contributor: fullname: Covvey – volume: 49 start-page: 493 year: 2015 end-page: 501 ident: bib0030 article-title: Emergency department visits and overdose deaths from combined use of opioids and benzodiazepines publication-title: American Journal of Preventive Medicine contributor: fullname: McAninch – year: 2018 ident: bib0071 article-title: FDA Drug Safety Communication: FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning – volume: 178 start-page: 643 year: 2021 end-page: 650 ident: bib0067 article-title: The risk of overdose with concomitant use of Z-drugs and prescription opioids: A population-based cohort study publication-title: American Journal of Psychiatry contributor: fullname: Huybrechts – volume: 34 start-page: 1 year: 2022 end-page: 8 ident: bib0014 article-title: Overdose death data suggests Z-drugs, gabapentinoids not without risks publication-title: Alcoholism & Drug Abuse Weekly contributor: fullname: Enos – volume: 327 year: 2022 ident: bib0039 article-title: Gabapentin increasingly implicated in overdose deaths publication-title: JAMA contributor: fullname: Kuehn – year: 2019 ident: bib0049 article-title: The synthetic opioid surge in the United States contributor: fullname: Stein – year: 2008 ident: bib0035 article-title: Effect of add-on gabapentin on opioid withdrawal symptoms in opium-dependent patients publication-title: Addiction contributor: fullname: Salehi – volume: 27 start-page: 5 year: 2014 end-page: 16 ident: bib0028 article-title: Benzodiazepines: A major component in unintentional prescription drug overdoses with opioid analgesics publication-title: Journal of Pharmacy Practice contributor: fullname: Lopez – volume: 26 start-page: 41 year: 2021 end-page: 50 ident: bib0013 article-title: Polysubstance use in the US opioid crisis publication-title: Molecular Psychiatry contributor: fullname: DuPont – year: 2022 ident: bib0075 article-title: Trends in concurrent opioid and benzodiazepine prescriptions in the United States, 2016 to 2019 publication-title: Annals of Internal Medicine contributor: fullname: Larochelle – year: 2022 ident: bib0044 article-title: Policy-induced substitution to illicit drugs and implications for law enforcement activity publication-title: American Journal of Health Economics contributor: fullname: Mallatt – volume: 77 start-page: 403 year: 2017 end-page: 426 ident: bib0018 article-title: Abuse and misuse of pregabalin and gabapentin publication-title: Drugs contributor: fullname: Saklad – volume: 101 start-page: 1 year: 2019 end-page: 15 ident: bib0017 article-title: How the reformulation of OxyContin ignited the heroin epidemic publication-title: Review of Economics and Statistics contributor: fullname: Power – volume: 38 start-page: 224 year: 2018 ident: bib0040 article-title: Evidence synthesis-The opioid crisis in Canada: A national perspective publication-title: Health Promotion and Chronic Disease Prevention in Canada: Research, Policy and Practice contributor: fullname: Jessica – volume: 23 start-page: 1238 year: 2014 end-page: 1246 ident: bib0062 article-title: Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation publication-title: Pharmacoepidemiology and drug safety contributor: fullname: Coplan – volume: 51 start-page: 151 year: 2016 end-page: 160 ident: bib0025 article-title: Trends in the concomitant prescribing of opioids and benzodiazepines, 2002−2014 publication-title: American Journal of Preventive Medicine contributor: fullname: McAninch – volume: 4 start-page: 504 year: 2018 end-page: 526 ident: bib0047 article-title: Prescription drug monitoring programs: The role of asymmetric information on drug availability and abuse publication-title: American Journal of Health Economics contributor: fullname: Meinhofer – volume: 227 year: 2021 ident: bib0034 article-title: Drug overdose deaths involving cocaine and psychostimulants with abuse potential among racial and ethnic groups–United States, 2004–2019 publication-title: Drug and Alcohol Dependence contributor: fullname: Davis – volume: 38 start-page: 287 year: 2019 end-page: 294 ident: bib0054 article-title: A transitioning epidemic: How the opioid crisis is driving the rise in hepatitis C publication-title: Health Affairs (Project Hope) contributor: fullname: Pacula – volume: 28 start-page: 1449 year: 2019 end-page: 1461 ident: bib0004 article-title: Adverse health effects of abuse-deterrent opioids: Evidence from the reformulation of OxyContin publication-title: Health Economics contributor: fullname: Beheshti – start-page: 443 issue: 15 year: 2022 ident: 10.1016/j.drugpo.2023.104104_bib0077 article-title: Geographic variation in the use of gabapentinoids and opioids for pain in a commercially insured adult population in the United States publication-title: Journal of Pain Research doi: 10.2147/JPR.S345521 contributor: fullname: Zhao – volume: 17 start-page: 55 issue: 2 year: 2018 ident: 10.1016/j.drugpo.2023.104104_bib0036 article-title: Gabapentin, pregabalin, and placebo in reducing opioid withdrawal symptoms in opioid-dependent individuals: A randomized-controlled trial publication-title: Addictive Disorders & Their Treatment doi: 10.1097/ADT.0000000000000127 contributor: fullname: Kheirabadi – volume: 18 issue: 7 year: 2021 ident: 10.1016/j.drugpo.2023.104104_bib0056 article-title: Mortality and concurrent use of opioids and hypnotics in older patients: A retrospective cohort study publication-title: PLoS Medicine doi: 10.1371/journal.pmed.1003709 contributor: fullname: Ray – year: 2022 ident: 10.1016/j.drugpo.2023.104104_bib0068 article-title: Overdose deaths involving non-BZD hypnotic/sedatives in the USA: Trends analyses publication-title: The Lancet Regional Health-Americas doi: 10.1016/j.lana.2022.100190 contributor: fullname: Tardelli – volume: 77 start-page: 403 issue: 4 year: 2017 ident: 10.1016/j.drugpo.2023.104104_bib0018 article-title: Abuse and misuse of pregabalin and gabapentin publication-title: Drugs doi: 10.1007/s40265-017-0700-x contributor: fullname: Evoy – volume: 64 issue: 1 year: 2021 ident: 10.1016/j.drugpo.2023.104104_bib0053 article-title: Is Europe facing an opioid crisis like the United States? An analysis of opioid use and related adverse effects in 19 European countries between 2010 and 2018 publication-title: European Psychiatry doi: 10.1192/j.eurpsy.2021.2219 contributor: fullname: Pierce – issue: 76 year: 2021 ident: 10.1016/j.drugpo.2023.104104_bib0050 article-title: Is the rise in illicit opioids affecting labor supply and disability claiming rates? publication-title: Journal of Health Economics contributor: fullname: Park – volume: 11 issue: 11 year: 2021 ident: 10.1016/j.drugpo.2023.104104_bib0015 article-title: Trends in prescribing pattern of opioid and benzodiazepine substitutes among Medicare Part D beneficiaries from 2013 to 2018: A retrospective study publication-title: BMJ Open doi: 10.1136/bmjopen-2021-053487 contributor: fullname: Esechie – year: 2017 ident: 10.1016/j.drugpo.2023.104104_bib0070 – volume: 71 start-page: 664 issue: 19 year: 2022 ident: 10.1016/j.drugpo.2023.104104_bib0045 article-title: Notes from the field: Trends in gabapentin detection and involvement in drug overdose deaths—23 states and the District of Columbia, 2019–2020 publication-title: Morbidity and Mortality Weekly Report doi: 10.15585/mmwr.mm7119a3 contributor: fullname: Mattson – volume: 227 year: 2021 ident: 10.1016/j.drugpo.2023.104104_bib0034 article-title: Drug overdose deaths involving cocaine and psychostimulants with abuse potential among racial and ethnic groups–United States, 2004–2019 publication-title: Drug and Alcohol Dependence doi: 10.1016/j.drugalcdep.2021.109001 contributor: fullname: Kariisa – volume: 9 start-page: 542 issue: 2 year: 2020 ident: 10.1016/j.drugpo.2023.104104_bib0006 article-title: Combining opioids and benzodiazepines: Effects on mortality and severe adverse respiratory events publication-title: Annals of Palliative Medicine doi: 10.21037/apm.2019.12.09 contributor: fullname: Boon – volume: 23 start-page: 1238 issue: 12 year: 2014 ident: 10.1016/j.drugpo.2023.104104_bib0062 article-title: Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation publication-title: Pharmacoepidemiology and drug safety doi: 10.1002/pds.3658 contributor: fullname: Sessler – year: 2022 ident: 10.1016/j.drugpo.2023.104104_bib0016 article-title: The hazards of unwinding the prescription opioid epidemic: Implications for child maltreatment publication-title: American Economic Journal: Economic Policy contributor: fullname: Evans – volume: 51 start-page: 151 issue: 2 year: 2016 ident: 10.1016/j.drugpo.2023.104104_bib0025 article-title: Trends in the concomitant prescribing of opioids and benzodiazepines, 2002−2014 publication-title: American Journal of Preventive Medicine doi: 10.1016/j.amepre.2016.02.014 contributor: fullname: Hwang – volume: 38 start-page: 287 issue: 2 year: 2019 ident: 10.1016/j.drugpo.2023.104104_bib0054 article-title: A transitioning epidemic: How the opioid crisis is driving the rise in hepatitis C publication-title: Health Affairs (Project Hope) doi: 10.1377/hlthaff.2018.05232 contributor: fullname: Powell – volume: 10 start-page: 1 issue: 4 year: 2018 ident: 10.1016/j.drugpo.2023.104104_bib0002 article-title: Supply-side drug policy in the presence of substitutes: Evidence from the introduction of abuse-deterrent opioids publication-title: American Economic Journal-Economic Policy doi: 10.1257/pol.20170082 contributor: fullname: Alpert – volume: 27 start-page: 5 issue: 1 year: 2014 ident: 10.1016/j.drugpo.2023.104104_bib0028 article-title: Benzodiazepines: A major component in unintentional prescription drug overdoses with opioid analgesics publication-title: Journal of Pharmacy Practice doi: 10.1177/0897190013515001 contributor: fullname: Jann – volume: 31 start-page: 593 issue: 5 year: 2011 ident: 10.1016/j.drugpo.2023.104104_bib0060 article-title: Importance of gabapentin dose in treatment of opioid withdrawal publication-title: Journal of clinical psychopharmacology doi: 10.1097/JCP.0b013e31822bb378 contributor: fullname: Salehi – start-page: 49 issue: 167 year: 2016 ident: 10.1016/j.drugpo.2023.104104_bib0074 article-title: Understanding opioid overdose characteristics involving prescription and illicit opioids: A mixed methods analysis publication-title: Drug and Alcohol Dependence doi: 10.1016/j.drugalcdep.2016.07.024 contributor: fullname: Yarborough – volume: 62 start-page: 468 issue: 2 year: 2022 ident: 10.1016/j.drugpo.2023.104104_bib0048 article-title: Co-utilization of opioids and nonbenzodiazepine hypnotic drugs in US ambulatory care visits, 2006–2016 publication-title: Journal of the American Pharmacists Association doi: 10.1016/j.japh.2021.10.020 contributor: fullname: Oueini – volume: 113 year: 2021 ident: 10.1016/j.drugpo.2023.104104_bib0020 article-title: The potential role of cocaine and heroin co-use in the opioid epidemic in the United States publication-title: Addictive Behaviors doi: 10.1016/j.addbeh.2020.106680 contributor: fullname: Goodwin – volume: 179 start-page: 695 issue: 5 year: 2019 ident: 10.1016/j.drugpo.2023.104104_bib0019 article-title: A clinical overview of off-label use of gabapentinoid drugs publication-title: JAMA Internal Medicine doi: 10.1001/jamainternmed.2019.0086 contributor: fullname: Goodman – volume: 71 start-page: 940 issue: 29 year: 2022 ident: 10.1016/j.drugpo.2023.104104_bib0033 article-title: Vital signs: Drug overdose deaths, by selected sociodemographic and social determinants of health characteristics—25 states and the District of Columbia, 2019–2020 publication-title: Morbidity and Mortality Weekly Report doi: 10.15585/mmwr.mm7129e2 contributor: fullname: Kariisa – volume: 4 start-page: 504 issue: 4 year: 2018 ident: 10.1016/j.drugpo.2023.104104_bib0047 article-title: Prescription drug monitoring programs: The role of asymmetric information on drug availability and abuse publication-title: American Journal of Health Economics doi: 10.1162/ajhe_a_00101 contributor: fullname: Meinhofer – volume: 57 start-page: 629 issue: 5 year: 2019 ident: 10.1016/j.drugpo.2023.104104_bib0021 article-title: An examination of concurrent opioid and benzodiazepine prescribing in 9 states, 2015 publication-title: American Journal of Preventive Medicine doi: 10.1016/j.amepre.2019.06.007 contributor: fullname: Guy Jr, Gery – volume: 113 start-page: 1339 issue: 7 year: 2018 ident: 10.1016/j.drugpo.2023.104104_bib0058 article-title: Corrected US opioid-involved drug poisoning deaths and mortality rates, 1999–2015 publication-title: Addiction doi: 10.1111/add.14144 contributor: fullname: Ruhm – volume: 72 start-page: 424 issue: 5 year: 2015 ident: 10.1016/j.drugpo.2023.104104_bib0010 article-title: Abuse-deterrent formulations and the prescription opioid abuse epidemic in the United States: Lessons learned from OxyContin publication-title: JAMA Psychiatry doi: 10.1001/jamapsychiatry.2014.3043 contributor: fullname: Cicero – volume: 110 start-page: 244 issue: 2 year: 2020 ident: 10.1016/j.drugpo.2023.104104_bib0012 article-title: Polysubstance use: A broader understanding of substance use during the opioid crisis publication-title: American Journal of Public Health doi: 10.2105/AJPH.2019.305412 contributor: fullname: Cicero – volume: 16 issue: 11 year: 2019 ident: 10.1016/j.drugpo.2023.104104_bib0043 article-title: Prescription of benzodiazepines, z-drugs, and gabapentinoids and mortality risk in people receiving opioid agonist treatment: Observational study based on the UK Clinical Practice Research Datalink and Office for National Statistics death records publication-title: PLoS Medicine doi: 10.1371/journal.pmed.1002965 contributor: fullname: Macleod – volume: 42 start-page: 154 issue: 1 year: 2020 ident: 10.1016/j.drugpo.2023.104104_bib0029 article-title: The evolving overdose epidemic: Synthetic opioids and rising stimulant-related harms publication-title: Epidemiologic Reviews doi: 10.1093/epirev/mxaa011 contributor: fullname: Jones – volume: 111 start-page: 1160 issue: 7 year: 2016 ident: 10.1016/j.drugpo.2023.104104_bib0065 article-title: Gabapentin misuse, abuse and diversion: A systematic review publication-title: Addiction doi: 10.1111/add.13324 contributor: fullname: Smith – volume: 32 start-page: 939 issue: 6 year: 2022 ident: 10.1016/j.drugpo.2023.104104_bib0061 article-title: Evidence of the emergence of illicit benzodiazepines from online drug forums publication-title: European Journal of Public Health doi: 10.1093/eurpub/ckac161 contributor: fullname: Sarker – volume: 399 start-page: 555 issue: 10324 year: 2022 ident: 10.1016/j.drugpo.2023.104104_bib0024 article-title: Responding to the opioid crisis in North America and beyond: Recommendations of the Stanford–Lancet commission publication-title: The Lancet doi: 10.1016/S0140-6736(21)02252-2 contributor: fullname: Humphreys – volume: 10 issue: 11 year: 2020 ident: 10.1016/j.drugpo.2023.104104_bib0064 article-title: Concurrent use of opioids and benzodiazepines/Z-drugs in Alberta, Canada and the risk of hospitalisation and death: A case cross-over study publication-title: BMJ Open doi: 10.1136/bmjopen-2020-038692 contributor: fullname: Sharma – volume: 49 start-page: 493 issue: 4 year: 2015 ident: 10.1016/j.drugpo.2023.104104_bib0030 article-title: Emergency department visits and overdose deaths from combined use of opioids and benzodiazepines publication-title: American Journal of Preventive Medicine doi: 10.1016/j.amepre.2015.03.040 contributor: fullname: Jones – volume: 4 start-page: e498 issue: 10 year: 2019 ident: 10.1016/j.drugpo.2023.104104_bib0032 article-title: Trends in use and misuse of opioids in the Netherlands: A retrospective, multi-source database study publication-title: The Lancet Public Health doi: 10.1016/S2468-2667(19)30128-8 contributor: fullname: Kalkman – volume: 38 start-page: 224 issue: 6 year: 2018 ident: 10.1016/j.drugpo.2023.104104_bib0040 article-title: Evidence synthesis-The opioid crisis in Canada: A national perspective publication-title: Health Promotion and Chronic Disease Prevention in Canada: Research, Policy and Practice doi: 10.24095/hpcdp.38.6.02 contributor: fullname: Lisa – year: 2019 ident: 10.1016/j.drugpo.2023.104104_bib0049 contributor: fullname: Pardo – volume: 42 start-page: zsy264 issue: 4 year: 2019 ident: 10.1016/j.drugpo.2023.104104_bib0073 article-title: Benzodiazepine and opioid co-usage in the US population, 1999–2014: An exploratory analysis publication-title: Sleep doi: 10.1093/sleep/zsy264 contributor: fullname: Vozoris – volume: 28 start-page: 1449 issue: 12 year: 2019 ident: 10.1016/j.drugpo.2023.104104_bib0004 article-title: Adverse health effects of abuse-deterrent opioids: Evidence from the reformulation of OxyContin publication-title: Health Economics doi: 10.1002/hec.3944 contributor: fullname: Beheshti – volume: 87 start-page: 1676 issue: 4 year: 2021 ident: 10.1016/j.drugpo.2023.104104_bib0023 article-title: Nonmedical use of benzodiazepines and Z-drugs in the UK publication-title: British Journal of Clinical Pharmacology doi: 10.1111/bcp.14397 contributor: fullname: Hockenhull – issue: 356 year: 2017 ident: 10.1016/j.drugpo.2023.104104_bib0066 article-title: Association between concurrent use of prescription opioids and benzodiazepines and overdose: Retrospective analysis publication-title: BMJ contributor: fullname: Sun – volume: 21 start-page: 3794 issue: 11 year: 2021 ident: 10.1016/j.drugpo.2023.104104_bib0041 article-title: Trends in nonfatal and fatal overdoses involving benzodiazepines—38 states and the District of Columbia, 2019–2020 publication-title: American Journal of Transplantation doi: 10.1111/ajt.16053 contributor: fullname: Liu – volume: 67 start-page: 349 issue: 12 year: 2018 ident: 10.1016/j.drugpo.2023.104104_bib0063 article-title: Overdose deaths involving opioids, cocaine, and psychostimulants—United States, 2015–2016 publication-title: Morbidity and Mortality Weekly Report doi: 10.15585/mmwr.mm6712a1 contributor: fullname: Seth – ident: 10.1016/j.drugpo.2023.104104_bib0027 – volume: 101 start-page: 1 issue: 1 year: 2019 ident: 10.1016/j.drugpo.2023.104104_bib0017 article-title: How the reformulation of OxyContin ignited the heroin epidemic publication-title: Review of Economics and Statistics doi: 10.1162/rest_a_00755 contributor: fullname: Evans – volume: 34 start-page: 344 issue: 4 year: 2021 ident: 10.1016/j.drugpo.2023.104104_bib0009 article-title: The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis publication-title: Current Opinion in Psychiatry doi: 10.1097/YCO.0000000000000717 contributor: fullname: Ciccarone – year: 2019 ident: 10.1016/j.drugpo.2023.104104_bib0072 – volume: 183 start-page: 162 issue: 2 year: 2023 ident: 10.1016/j.drugpo.2023.104104_bib0052 article-title: Trends in the concurrent prescription of opioids and Gabapentin in the US, 2006 to 2018 publication-title: JAMA Internal Medicine doi: 10.1001/jamainternmed.2022.5268 contributor: fullname: Peet – volume: 6 start-page: 662 issue: 10 year: 2005 ident: 10.1016/j.drugpo.2023.104104_bib0011 article-title: Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004 publication-title: The Journal of Pain doi: 10.1016/j.jpain.2005.05.004 contributor: fullname: Cicero – volume: 76 start-page: 1208 issue: 11 year: 2019 ident: 10.1016/j.drugpo.2023.104104_bib0076 article-title: Opioid and benzodiazepine coprescribing in the United States before and after US Food and Drug Administration boxed warning publication-title: JAMA Psychiatry doi: 10.1001/jamapsychiatry.2019.2563 contributor: fullname: Zhang – year: 2008 ident: 10.1016/j.drugpo.2023.104104_bib0035 article-title: Effect of add-on gabapentin on opioid withdrawal symptoms in opium-dependent patients publication-title: Addiction doi: 10.1111/j.1360-0443.2008.02248.x contributor: fullname: Kheirabadi – volume: 27 start-page: 1185 issue: 12 year: 2017 ident: 10.1016/j.drugpo.2023.104104_bib0005 article-title: How addictive are gabapentin and pregabalin? A systematic review publication-title: European Neuropsychopharmacology doi: 10.1016/j.euroneuro.2017.08.430 contributor: fullname: Bonnet – volume: 107 start-page: 430 issue: 3 year: 2017 ident: 10.1016/j.drugpo.2023.104104_bib0046 article-title: Recent increases in cocaine-related overdose deaths and the role of opioids publication-title: American journal of public health doi: 10.2105/AJPH.2016.303627 contributor: fullname: McCall Jones – volume: 3 issue: 12 year: 2020 ident: 10.1016/j.drugpo.2023.104104_bib0007 article-title: Association of gabapentinoids with the risk of opioid-related adverse events in surgical patients in the United States publication-title: JAMA Network Open doi: 10.1001/jamanetworkopen.2020.31647 contributor: fullname: Bykov – volume: 178 start-page: 643 issue: 7 year: 2021 ident: 10.1016/j.drugpo.2023.104104_bib0067 article-title: The risk of overdose with concomitant use of Z-drugs and prescription opioids: A population-based cohort study publication-title: American Journal of Psychiatry doi: 10.1176/appi.ajp.2020.20071038 contributor: fullname: Szmulewicz – year: 2018 ident: 10.1016/j.drugpo.2023.104104_bib0071 – issue: 111 year: 2023 ident: 10.1016/j.drugpo.2023.104104_bib0059 article-title: The increase in benzodiazepine-laced drugs and related risks in Canada: The urgent need for effective and sustainable solutions publication-title: International Journal of Drug Policy contributor: fullname: Russell – start-page: 219 issue: 3 year: 2017 ident: 10.1016/j.drugpo.2023.104104_bib0057 article-title: Drug involvement in fatal overdoses publication-title: SSM-Population Health doi: 10.1016/j.ssmph.2017.01.009 contributor: fullname: Ruhm – volume: 191 start-page: 599 issue: 4 year: 2022 ident: 10.1016/j.drugpo.2023.104104_bib0069 article-title: Racial/Ethnic and geographic trends in combined stimulant/opioid overdoses, 2007–2019 publication-title: American Journal of Epidemiology doi: 10.1093/aje/kwab290 contributor: fullname: Townsend – year: 2022 ident: 10.1016/j.drugpo.2023.104104_bib0044 article-title: Policy-induced substitution to illicit drugs and implications for law enforcement activity publication-title: American Journal of Health Economics doi: 10.1086/716462 contributor: fullname: Mallatt – volume: 28 start-page: 231 issue: 3 year: 2022 ident: 10.1016/j.drugpo.2023.104104_bib0031 article-title: Monitoring opioids in Europe: The need for shared definitions and measuring drivers of opioid use and related harms publication-title: European Addiction Research doi: 10.1159/000521996 contributor: fullname: Kalkman – year: 2022 ident: 10.1016/j.drugpo.2023.104104_bib0075 article-title: Trends in concurrent opioid and benzodiazepine prescriptions in the United States, 2016 to 2019 publication-title: Annals of Internal Medicine doi: 10.7326/M21-4656 contributor: fullname: Zhang – volume: 75 year: 2021 ident: 10.1016/j.drugpo.2023.104104_bib0037 article-title: Must-access prescription drug monitoring programs and the opioid overdose epidemic: The unintended consequences publication-title: Journal of Health Economics doi: 10.1016/j.jhealeco.2020.102408 contributor: fullname: Kim – volume: 327 issue: 24 year: 2022 ident: 10.1016/j.drugpo.2023.104104_bib0039 article-title: Gabapentin increasingly implicated in overdose deaths publication-title: JAMA doi: 10.1001/jama.2022.10100 contributor: fullname: Kuehn – start-page: 559 issue: 36 year: 2015 ident: 10.1016/j.drugpo.2023.104104_bib0038 article-title: The prescription opioid and heroin crisis: A public health approach to an epidemic of addiction publication-title: Annual Review of Public Health doi: 10.1146/annurev-publhealth-031914-122957 contributor: fullname: Kolodny – volume: 34 start-page: 1 issue: 10 year: 2022 ident: 10.1016/j.drugpo.2023.104104_bib0014 article-title: Overdose death data suggests Z-drugs, gabapentinoids not without risks publication-title: Alcoholism & Drug Abuse Weekly doi: 10.1002/adaw.33367 contributor: fullname: Enos – volume: 87 start-page: 1684 issue: 4 year: 2021 ident: 10.1016/j.drugpo.2023.104104_bib0022 article-title: Non-medical use of benzodiazepines and GABA analogues in Europe publication-title: British Journal of Clinical Pharmacology doi: 10.1111/bcp.14537 contributor: fullname: Hockenhull – volume: 70 start-page: 1177 issue: 34 year: 2021 ident: 10.1016/j.drugpo.2023.104104_bib0001 article-title: Notes from the field: Illicit benzodiazepines detected in patients evaluated in Emergency Departments for Suspected Opioid Overdose—Four States, October 6, 2020–March 9, 2021 publication-title: Morbidity and Mortality Weekly Report doi: 10.15585/mmwr.mm7034a4 contributor: fullname: Aldy – year: 2022 ident: 10.1016/j.drugpo.2023.104104_bib0026 publication-title: ICD List – volume: 95 start-page: 36 issue: 1 year: 2021 ident: 10.1016/j.drugpo.2023.104104_bib0042 article-title: From fostering hope to lingering harm: The unintended impact of the OxyContin reformulation on child welfare utilization publication-title: Social Service Review doi: 10.1086/713378 contributor: fullname: Mackenzie-Liu – volume: 16 start-page: 1263 issue: 11 year: 2016 ident: 10.1016/j.drugpo.2023.104104_bib0008 article-title: Alpha2delta ligands, gabapentin, pregabalin and mirogabalin: A review of their clinical pharmacology and therapeutic use publication-title: Expert Review of Neurotherapeutics doi: 10.1080/14737175.2016.1202764 contributor: fullname: Calandre – volume: 26 start-page: 41 issue: 1 year: 2021 ident: 10.1016/j.drugpo.2023.104104_bib0013 article-title: Polysubstance use in the US opioid crisis publication-title: Molecular Psychiatry doi: 10.1038/s41380-020-00949-3 contributor: fullname: Compton – volume: 12 year: 2018 ident: 10.1016/j.drugpo.2023.104104_bib0051 article-title: Gabapentin for off-label use: Evidence-based or cause for concern? publication-title: Substance Abuse: Research and Treatment contributor: fullname: Peckham – volume: 7 start-page: 41 issue: 1 year: 2021 ident: 10.1016/j.drugpo.2023.104104_bib0055 article-title: The evolving consequences of OxyContin reformulation on drug overdoses publication-title: American Journal of Health Economics doi: 10.1086/711723 contributor: fullname: Powell – volume: 137 start-page: 1139 issue: 2 year: 2022 ident: 10.1016/j.drugpo.2023.104104_bib0003 article-title: Origins of the opioid crisis and its enduring impacts publication-title: The Quarterly Journal of Economics doi: 10.1093/qje/qjab043 contributor: fullname: Alpert |
| SSID | ssj0004141 |
| Score | 2.3851616 |
| Snippet | Previous studies demonstrate that the reformulation of OxyContin in the U.S. in 2010 induced substitution to illicit opioids, causing illicit opioid markets to... BACKGROUNDPrevious studies demonstrate that the reformulation of OxyContin in the U.S. in 2010 induced substitution to illicit opioids, causing illicit opioid... |
| SourceID | proquest crossref pubmed elsevier |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 104104 |
| SubjectTerms | Benzodiazepines Gabapentinoids Illicit drug markets Opioid crisis OxyContin reformulation Z-drugs |
| Title | Understanding the rise in overdose deaths involving opioids and non-opioid prescription drugs in the United States |
| URI | https://dx.doi.org/10.1016/j.drugpo.2023.104104 https://www.ncbi.nlm.nih.gov/pubmed/37422359 https://search.proquest.com/docview/2835280342 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB7R5cKlKlDabQEZqeKEu5vETjZHhEBbEAiprMrNcvyo0lbJKrt74MJvZyZOWCq1qtRb7GQcy-PMfM68AD7p3GSRkJ7HVlMJMz_mOrU5TxNnM1GMrWiTVV_fpNOZuLyX9xtw1sfCkFtlJ_uDTG-lddcz6lZzNC_L0VdKnpbkEhEKKX6qNLzZGokGsHn65Wp6sw6PDAUs6XlOBH0EXevmZZvV9zlFAcYJ2TujrmLbHzTU3xBoq4ku3sDrDkKy0zDLbdhw1Q4c34Yc1A8n7G4dUrU4Ycfsdp2d-mEH9kNALvvmfnndOLzfd9TNz11oZi-jXRjCQ4ZiwLGyYuTsaWu8tgQbF9iFoo3-R7B6XtalXTAkYlVd8dBm5GPbCyVGK0A07ZAB6bKAdN_C7OL87mzKu7oM3MRZtuRWem9iH_lE2jTyYmwmwhRmkhvvLUEAiWcoVIIST49y4hEYJ5mWFqGUzIQUJtmDAU7GvQcW6dzriSicHjuhtcljl-Y4otcekU0hh8B7Xqh5SL-her-0HyrwThHvVODdELKeYeq3baRQQ_yD8qjnr8IvjMwmunL1aqEoIx3V8BLxEN4Fxj_PJckE4iuZf_jv936ELWq1HsDpPgyWzcodIM5ZFofw6vNjdNjt5ichZP5H |
| link.rule.ids | 315,783,787,4511,24130,27938,27939,45599,45693 |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwED9N2wO8IBhfhQFGQnua1Saxk_pxmpg6tlWTaMXeLMcfUwAlVdo-7L_nLk4oSCAk3hI755x8zt3P8X0AfDDKFomQgafOUAmzMOEmd4rnmXeFKCdOdMmqr-f5bCk-3crbPTgbYmHIrbLX_VGnd9q6bxn3szleVdX4MyVPy5REhEKGnyoNHyAaULjYD04vLmfzXXhkLGBJz3MiGCLoOjcv127vVhQFmGZ03pn0Fdv-YKH-hkA7S3T-GB71EJKdRi6fwJ6vD-H4Juagvj9hi11I1fqEHbObXXbq-0M4igG57Iv_HkzrsX9oaNpvT6Fd_hrtwhAeMlQDnlU1I2dP1-C1I9i4xiZUbfQ_gjWrqqncmiERq5uax3tGPraDUmI0A0TTDRmRLotI9xkszz8uzma8r8vAbVoUG-5kCDYNSciky5MgJnYqbGmnyobgCAJI3EOhEZS4e5TTgMA4K4x0CKVkIaSw2XPYR2b8S2CJUcFMRenNxAtjrEp9rnDEYAIim1KOgA-y0KuYfkMPfmlfdZSdJtnpKLsRFIPA9G_LSKOF-Afl-0G-Gr8wOjYxtW-2a00Z6aiGl0hH8CIK_icvWSEQX0n16r_f-w4ezBbXV_rqYn75Gh5ST-cNnB_B_qbd-jeIeTbl235N_wBg0wBT |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Understanding+the+rise+in+overdose+deaths+involving+opioids+and+non-opioid+prescription+drugs+in+the+United+States&rft.jtitle=The+International+journal+of+drug+policy&rft.au=Powell%2C+David&rft.au=Peet%2C+Evan+D&rft.au=Pacula%2C+Rosalie+Liccardo&rft.date=2023-07-06&rft.eissn=1873-4758&rft.spage=104104&rft_id=info:doi/10.1016%2Fj.drugpo.2023.104104&rft_id=info%3Apmid%2F37422359&rft.externalDocID=37422359 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0955-3959&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0955-3959&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0955-3959&client=summon |